Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 20, 2022

Primary Completion Date

October 24, 2024

Study Completion Date

October 24, 2024

Conditions
MetrorrhagiaPelvic PainMenorrhagiaLeiomyoma
Interventions
DRUG

Myfembree Oral Product

The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.

Trial Locations (6)

46375

University of Chicago Schererville, Schererville

60422

University of Chicago Flossmoor, Flossmoor

60462

University of Chicago Orland Park, Orland Park

60607

University of Chicago South Loop, Chicago

60611

University of Chicago River East, Chicago

60637

University of Chicago DCAM, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Myovant Sciences GmbH

INDUSTRY

lead

University of Chicago

OTHER